The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors
Explore this paper's citation graph
Summary
A brief introduction to immune checkpoint inhibitors is provided, the most common irAEs relevant to emergency physicians are discussed, and suggestions on how to manage patients presenting to the emergency department (ED) suffering fromirAEs are given.
- Type
- review
- Published
- 2017-10-01
- Cited by
- 25
- References
- 41
- Access
- Open access
- OpenAlex
- https://openalex.org/W2761191882
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12074500
Keywords
Medicine, Adverse effect, Immune system, Immune checkpoint, Melanoma
References
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- Managing immune checkpoint-blocking antibody side effects.
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Endocrine side effects induced by immune checkpoint inhibitors.
- 9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- The blockade of immune checkpoints in cancer immunotherapy
- A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis
- Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
- Management of immune-related adverse events and kinetics of response with ipilimumab.
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
- Nivolumab in previously untreated melanoma without BRAF mutation.
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Cited by
- Modern approaches to kidney cancer immunotherapy
- Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment
- Leberschaden durch Therapie mit Immun-Checkpoint-Inhibitoren
- Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
- Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis
- Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
- Immunotherapy Adverse Events: An Emergency Nursing Perspective.
- Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
- Oncologic emergencies in the emergency medicine residency curriculum: A national survey.
- ИНГИБИТОРЫ КОНТРОЛЬНЫХ ТОЧЕК ИММУННОГО ОТВЕТА: НОВЫЕ РИСКИ НОВОГО КЛАССА ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ
- Oncologic Emergencies: Immune-Based Cancer Therapies and Complications
- Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors
- Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
- Management of Hospital Admissions for Checkpoint Inhibitor Immune-Related Adverse Events at a Regional Cancer Center
- Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
- Evaluation of Knowledge of Immunotherapy Toxicities Among Emergency Physicians in Riyadh, Saudi Arabia
- Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
- Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers
- A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors.
- Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department
Related papers
- A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
- Severe infusion reaction due to nivolumab: A case report
- P2.04-39 Clinical Characteristics of Long-Term Survivors with Nivolumab in Previously Treated Advanced NSCLC from Real World Data
- Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
- Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab
- Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma
- Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
- Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer